CO6400202A2 - Derivados de quinazolinona útiles como antagonistas de vanilloides - Google Patents

Derivados de quinazolinona útiles como antagonistas de vanilloides

Info

Publication number
CO6400202A2
CO6400202A2 CO11092089A CO11092089A CO6400202A2 CO 6400202 A2 CO6400202 A2 CO 6400202A2 CO 11092089 A CO11092089 A CO 11092089A CO 11092089 A CO11092089 A CO 11092089A CO 6400202 A2 CO6400202 A2 CO 6400202A2
Authority
CO
Colombia
Prior art keywords
formula
compound
useful
quinazolinone derivatives
preparation
Prior art date
Application number
CO11092089A
Other languages
English (en)
Spanish (es)
Inventor
Weichun Chen
Hong-Yong Kim
Jessica Liang
Michael Mutz
Mahavir Prashad
Christopher Towler
Ruoqiu Wu
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42167396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6400202(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CO6400202A2 publication Critical patent/CO6400202A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO11092089A 2009-01-13 2011-07-22 Derivados de quinazolinona útiles como antagonistas de vanilloides CO6400202A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14425009P 2009-01-13 2009-01-13

Publications (1)

Publication Number Publication Date
CO6400202A2 true CO6400202A2 (es) 2012-03-15

Family

ID=42167396

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11092089A CO6400202A2 (es) 2009-01-13 2011-07-22 Derivados de quinazolinona útiles como antagonistas de vanilloides

Country Status (28)

Country Link
US (2) US8349852B2 (enExample)
EP (1) EP2387440B1 (enExample)
JP (1) JP2012515150A (enExample)
KR (1) KR20110104996A (enExample)
CN (1) CN102281920A (enExample)
AR (1) AR075006A1 (enExample)
AU (1) AU2010206233B2 (enExample)
BR (1) BRPI1006909A2 (enExample)
CA (2) CA2749529C (enExample)
CO (1) CO6400202A2 (enExample)
CR (1) CR20110369A (enExample)
CU (1) CU20110148A7 (enExample)
EA (1) EA201101063A1 (enExample)
EC (1) ECSP11011195A (enExample)
ES (1) ES2614612T3 (enExample)
IL (1) IL213869A0 (enExample)
MA (1) MA32957B1 (enExample)
MX (1) MX2011007444A (enExample)
NZ (1) NZ593877A (enExample)
PE (1) PE20110776A1 (enExample)
PL (1) PL2387440T3 (enExample)
PT (1) PT2387440T (enExample)
SG (1) SG172808A1 (enExample)
TN (1) TN2011000326A1 (enExample)
TW (1) TW201036951A (enExample)
UY (1) UY32381A (enExample)
WO (1) WO2010084050A2 (enExample)
ZA (1) ZA201104873B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
KR20140097127A (ko) * 2011-09-16 2014-08-06 포비어 파마수티칼스 아닐린 유도체, 그의 제조법 및 그의 치료 용도
KR101789430B1 (ko) * 2016-06-28 2017-10-25 동국대학교 산학협력단 Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN111393380A (zh) * 2018-07-09 2020-07-10 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CN113453686B (zh) 2019-02-15 2025-04-15 博士伦爱尔兰有限公司 治疗眼表痛的方法
EP3924345A1 (en) * 2019-02-15 2021-12-22 Novartis AG Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
US20220257596A1 (en) 2019-07-15 2022-08-18 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
IL292161B2 (en) 2019-12-10 2025-04-01 Hoffmann La Roche New methylquinazolinone derivatives
EP4192466A1 (en) 2020-08-06 2023-06-14 Novartis AG Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
WO2022074557A1 (en) 2020-10-07 2022-04-14 Novartis Ag Drug containing dissolvable ocular inserts and method of using same
CN116456986A (zh) * 2020-11-17 2023-07-18 苏州晶云药物科技股份有限公司 一种喹唑啉酮衍生物的新晶型及其制备方法

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE19735879A1 (de) 1997-08-19 1999-02-25 Hoechst Schering Agrevo Gmbh Verfahren zur Herstellung von 2-Carboxy-5-nitro-benzolsulfonsäure und deren Salzen durch Oxidation
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
DE69913548T2 (de) 1998-10-02 2004-09-23 Novartis Ag Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
JP4205430B2 (ja) 2001-03-26 2009-01-07 ノバルティス アクチエンゲゼルシャフト 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体
JP3894035B2 (ja) 2001-07-04 2007-03-14 東レ株式会社 炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
WO2005013997A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
DE602004009200T2 (de) 2003-08-12 2008-07-10 F. Hoffmann-La Roche Ag Tetrahydrochinazolinderivate als cfr-antagonisten
EP1664010A1 (en) 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
OA13248A (en) 2003-09-03 2007-01-31 Pfizer Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2007504271A (ja) 2003-09-05 2007-03-01 ニューロジェン・コーポレーション Ｃｒｆ１受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類
EP1666468A4 (en) 2003-09-09 2007-03-21 Ono Pharmaceutical Co CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
HRP20060126A2 (en) 2003-09-30 2008-05-31 Janssen Pharmaceutica N.V. Benzoimidazole compounds
WO2005033088A1 (en) 2003-09-30 2005-04-14 Janssen Pharmaceutica N.V. Quinoxaline compounds
EP1677789A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
JP2007510741A (ja) 2003-11-10 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としての置換トリアゾール類
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
CN1906187A (zh) 2003-12-19 2007-01-31 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5配体的5－氟－,氯－和氰基－吡啶－2－基－四唑类化合物
JP2005206590A (ja) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp ナトリウムチャネルサイト２選択的阻害剤
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
DE602005005167T2 (de) 2004-01-29 2009-04-30 Pfizer Inc. 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1716130A1 (en) 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
WO2005080379A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
MY152888A (en) 2004-02-18 2014-11-28 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
MY145075A (en) 2004-02-18 2011-12-15 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists.
JP2007523181A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538180A (en) 2004-02-20 2005-12-01 Astrazeneca Ab New compounds
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
WO2005092066A2 (en) 2004-03-25 2005-10-06 Janssen Pharmaceutica N.V. Imidazole compounds
WO2005097136A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
WO2005097788A2 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
EA010891B9 (ru) 2004-06-15 2012-08-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006006740A1 (ja) 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
EP2314585B1 (en) 2004-07-15 2012-09-12 Japan Tobacco, Inc. Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity
ES2333889T3 (es) 2004-07-19 2010-03-02 Institut De Recherche Pour Le Developpement (Ird) Composiciones farmaceuticas para el tratamiento de la leishmaniasis.
WO2006010629A1 (en) 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
WO2006016218A1 (en) 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
US7335672B2 (en) 2004-09-13 2008-02-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
SE0402284D0 (sv) 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
CN101039942A (zh) 2004-09-27 2007-09-19 伊利舍医药品公司 磺酰胺类及其用途
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
JP5635727B2 (ja) 2004-10-07 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法
EP1799661A1 (en) 2004-10-08 2007-06-27 AstraZeneca AB New hydroxymethylbenzothiazoles amides
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2583392A1 (en) 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
WO2006047492A2 (en) 2004-10-22 2006-05-04 Amgen Inc. Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
ATE431824T1 (de) 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
AU2005303893A1 (en) 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
AU2005316972B2 (en) 2004-11-24 2011-11-10 Abbvie Inc. Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
US7875627B2 (en) 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7615570B2 (en) 2004-12-13 2009-11-10 Abbott Laboratories Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
SE0403118D0 (sv) 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 2
SE0403117D0 (sv) 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
ATE469897T1 (de) 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
WO2006076646A2 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006078907A1 (en) 2005-01-20 2006-07-27 Amgen Inc. 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1848716A1 (en) 2005-02-17 2007-10-31 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
GB0503646D0 (en) 2005-02-22 2005-03-30 Novartis Ag Organic compounds
NZ556629A (en) 2005-03-03 2010-04-30 Janssen Pharmaceutica Nv Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
MX2007011105A (es) 2005-03-10 2007-10-08 Pfizer Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
US20060211710A1 (en) 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
EP1863756A1 (en) 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
US20060293309A1 (en) 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1877400A1 (en) 2005-04-15 2008-01-16 Amgen, Inc Vanilloid receptor ligands and their use in treatments
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
WO2006116563A1 (en) 2005-04-25 2006-11-02 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0508318D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508314D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006244027A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1)
JP4862042B2 (ja) 2005-05-11 2012-01-25 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）のアンタゴニスト及びその使用
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
EP1885348A2 (en) 2005-05-12 2008-02-13 Amgen, Inc Antipyretic agents against vr1-antagonist-induced increases in body temperature
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP2008540635A (ja) 2005-05-18 2008-11-20 アデックス ファーマ ソシエテ アノニム 代謝型グルタミン酸受容体の正のアロステリック調節因子としての置換されたオキシジアゾール誘導体
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
GB0510140D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005024012A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
US7582611B2 (en) 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7317022B2 (en) 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
EA200800013A1 (ru) 2005-06-10 2008-06-30 Эликсир Фармасьютикалз, Инк. Сульфонамидные соединения и их применение
WO2006137790A1 (en) 2005-06-23 2006-12-28 Astrazeneca Ab New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
EP1899318A4 (en) 2005-06-23 2010-03-17 Astrazeneca Ab NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
JP2009500419A (ja) 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
US20090170872A1 (en) 2005-07-05 2009-07-02 Orchid Research Laboratories Limited Compounds and Their Pharmaceutical Use
WO2007007018A1 (en) 2005-07-12 2007-01-18 Glaxo Group Limited Piperazine heteroaryl derivates as gpr38 agonists
EP1910340B1 (en) 2005-07-22 2009-11-18 Pfizer, Inc. Indazolecarboxamide derivatives as 5ht4 receptor agonists
WO2007014258A2 (en) 2005-07-22 2007-02-01 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
WO2007023245A1 (en) 2005-08-25 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
US20090105259A1 (en) 2005-09-08 2009-04-23 Jeong Jae U Acyclic 1,4-Diamines and Uses Thereof
AU2006290715A1 (en) 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine H4 receptor activity
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
AR056087A1 (es) 2005-09-29 2007-09-19 Astrazeneca Ab Derivados de azetidina como antagonistas de receptores de neuroquina nk
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
HUP0500921A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
CA2624307C (en) 2005-10-07 2014-04-29 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
US20070088073A1 (en) 2005-10-19 2007-04-19 Allergan, Inc. Method for treating pain
US7902251B2 (en) 2005-10-19 2011-03-08 Allergan, Inc. Method for treating pain
DK1940821T3 (da) 2005-10-19 2013-06-10 Gruenenthal Gmbh Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
AU2006306146A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007090854A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
EP1829879A1 (en) 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007090853A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007113202A1 (en) 2006-03-31 2007-10-11 Glaxo Group Limited Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
CA2648036C (en) 2006-03-31 2012-05-22 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
EP2004188B1 (en) 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
JP5132673B2 (ja) 2006-04-07 2013-01-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
EP2007716A1 (en) 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists

Also Published As

Publication number Publication date
JP2012515150A (ja) 2012-07-05
TW201036951A (en) 2010-10-16
CA2749529C (en) 2017-04-04
UY32381A (es) 2010-08-31
WO2010084050A2 (en) 2010-07-29
KR20110104996A (ko) 2011-09-23
CN102281920A (zh) 2011-12-14
PT2387440T (pt) 2017-01-17
PL2387440T3 (pl) 2017-09-29
IL213869A0 (en) 2011-07-31
SG172808A1 (en) 2011-08-29
CU20110148A7 (es) 2012-02-15
US20100197705A1 (en) 2010-08-05
US20130060029A1 (en) 2013-03-07
CA2749529A1 (en) 2010-07-29
AR075006A1 (es) 2011-03-02
AU2010206233B2 (en) 2012-07-26
AU2010206233A1 (en) 2011-07-28
ECSP11011195A (es) 2011-08-31
EA201101063A1 (ru) 2012-02-28
EP2387440B1 (en) 2016-11-09
TN2011000326A1 (en) 2012-12-17
MX2011007444A (es) 2011-08-12
WO2010084050A3 (en) 2011-01-27
PE20110776A1 (es) 2011-11-04
NZ593877A (en) 2012-11-30
US8349852B2 (en) 2013-01-08
ES2614612T3 (es) 2017-06-01
ZA201104873B (en) 2012-07-25
CA2946304A1 (en) 2010-07-29
BRPI1006909A2 (pt) 2016-02-16
CR20110369A (es) 2011-08-26
EP2387440A2 (en) 2011-11-23
MA32957B1 (fr) 2012-01-02

Similar Documents

Publication Publication Date Title
CO6400202A2 (es) Derivados de quinazolinona útiles como antagonistas de vanilloides
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR079498A1 (es) Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EA201201167A1 (ru) Соединения в качестве антагонистов брадикинина b1
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
TR201802791T4 (tr) Aril ve heteroaril füzyonlu laktamlar.
CO2019005824A2 (es) Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
AR076688A1 (es) Derivados de isoquinolin-1(2h)-ona
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
MX2010003849A (es) Antagonistas de cgrp.
AR079497A1 (es) Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a
ECSP109978A (es) Nuevos compuestos
DOP2009000073A (es) Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp.
EA201201662A1 (ru) Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1
AR110791A1 (es) Promotores de la germinación
AR071005A1 (es) Preparacion selectiva de pirimidinas sustituidas
EA201071014A1 (ru) Новые 7-замещенные производные 3-карбоксиоксадиазинохинолонов, способ их получения и применение в качестве антибактериальных средств

Legal Events

Date Code Title Description
FC Application refused